Abstract
Living donor liver transplantation (LDLT) is indicated for a variety of metabolic disorders, primarily in Asian countries due to the absolute scarcity of deceased donor liver transplantation (LT). We analyzed data for all pediatric LDLTs performed between November 1989 and December 2010, during which 2,224 pediatric patients underwent LDLT in Japan. Of these patients, 194 (8.7%) underwent LDLT for metabolic disorders. Wilson’s disease (n=59; 30.4%) was the most common indication in the patients with metabolic disorders, followed by ornithine transcarbamylase deficiency (OTCD; n=40; 20.6%), methylmalonic acidemia (MMA; n=20, 10.3%) and glycogen storage disease (GSD; n=15, 7.7%).Figure: No Caption available.The 1-, 5-, 10- and 15-year patient and graft survival rates were 91.2%, 87.9%, 87.0% and 79.3% and 91.2%, 87.9%, 86.1% and 74.4%, respectively.Figure: No Caption available.Wilson’s disease and urea cycle deficiency were associated with better patient survival. The use of heterozygous donors demonstrated no negative impact on either the donors or recipients. With regard to X-linked OTCD, symptomatic heterozygote maternal donors should not be considered potential donor candidates. Improving the understanding of the long-term suitability of this treatment modality will require the registration and ongoing evaluation of all patients with inherited metabolic disease considered for LT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.